Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

FDA Approves RCC Drug, Prostate Cancer and Smoking Link: April News Roundup

April 29, 2016
By Cancer Network Editors
Slideshow

This slide show highlights some of the top stories of the month, including the approval of a new agent for RCC, a study that found declines in prostate cancer deaths have mirrored the declines in smoking rates, and more.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Related Content

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

Russ Conroy
September 4th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 4th 2025
Podcast

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Ariana Pelosci
September 4th 2025
Article

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
September 4th 2025
Podcast

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Tim Cortese
September 4th 2025
Article

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 4th 2025
Article
Related Content

Patients with recurrent or metastatic cervical cancer in Hong Kong are now eligible to receive treatment with tisotumab vedotin.

Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer

Russ Conroy
September 4th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 4th 2025
Podcast

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Health Canada Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Ariana Pelosci
September 4th 2025
Article

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
September 4th 2025
Podcast

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Chemo/Radiation Did Not Yield Increased Pelvic Malignancies in Rectal Cancer

Tim Cortese
September 4th 2025
Article

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

Impact of Posttransplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 Years and Older: An Update from BMT CTN 1703

American Society for Transplantation and Cellular Therapy
September 4th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.